（原标题：艾迪药业(688488.SH)：补缴税款共计约1995.20万元） 格隆汇1月25日丨艾迪药业(688488.SH)公布，根据扬州市税务部门的通知，公司需补缴税款共计约 1,995.20万元。公司将按照要求于15日内将上述税款全部缴纳完毕。本次补缴税款不涉及滞纳金，不涉 及行政处罚，上述税款计入2025年度当期损益。 ...

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a gain of 1.26% on January 23, 2025, outperforming the CSI 300 index by 1.71 percentage points, ranking 10th among 31 sub-industries in the Shenwan classification. Notable performers included offline pharmacies (+6.79%), pharmaceutical distribution (+2.66%), and vaccines (+2.26%), while blood products (+0.58%), medical R&D outsourcing (+0.68%), and in vitro diagnostics (+1.37%) lagged behind [4]. - Takeda's new drug Oveporexton has been proposed for priority review by the National Medical Products Administration (NMPA) in China, aimed at treating narcolepsy type 1 in patients aged 16 and above. The drug has shown positive results in two pivotal Phase 3 studies [5]. Sub-industry Summary - Chemical Pharmaceuticals: No rating [3] - Traditional Chinese Medicine: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other Pharmaceuticals: Neutral [3]

Core Viewpoint - Northeast Pharmaceutical aims to implement a "main business focus, comprehensive industrial expansion" strategy, emphasizing "innovation-driven, digital empowerment, green transformation, and open cooperation" to enhance its competitiveness across the entire industry chain [1] Group 1 - The company plans to transition from a traditional chemical pharmaceutical enterprise to an innovative, international, diversified, and high-quality pharmaceutical health industry group [1] - The strategic focus includes two dimensions: targeting industry high points and horizontal development in the health sector [1]

Group 1: Strategic Planning and Business Model - Northeast Pharmaceutical aims to implement a "main business focus, comprehensive industrial expansion" strategy to enhance profitability and establish a sustainable profit model, maintaining stable growth in line with industry standards [2][3] - The company emphasizes "innovation-driven, digital empowerment, green transformation, and open cooperation" as core strategic directions to build competitive advantages across the entire industry chain [2] Group 2: Impact of Shareholder Changes - After becoming a controlling shareholder in 2018, Fangda Group introduced advanced market-oriented management models, significantly improving Northeast Pharmaceutical's operational efficiency and profitability [4] - The company has shown continuous profit growth over the past five years, indicating resilience and sustainable development capabilities [4] Group 3: Revenue Structure and Future Trends - As of the first three quarters of 2023, the company's revenue structure is stable, with approximately 60% from pharmaceutical manufacturing and 40% from pharmaceutical commerce [6] - Traditional businesses face challenges from industry policies and market competition, while innovative drug segments are expected to drive future growth [6][7] Group 4: Innovation and R&D Developments - The acquisition of a 70% stake in Beijing Dingcheng Peptide Source Biotech Co., Ltd. in 2024 allows Northeast Pharmaceutical to enter the TCR-T and CAR-T cell therapy fields, with promising products already in clinical trials [4][6] - Dingcheng Peptide has established a comprehensive R&D system, focusing on cell and gene therapy, and has received multiple recognitions as a high-tech enterprise [9][10] Group 5: Challenges and Market Dynamics - The company faces challenges in balancing high R&D costs with short-term cash flow pressures, particularly in the competitive cell therapy market [7] - The transition from traditional chemical pharmaceuticals to a dual-driven model of traditional and innovative biopharmaceuticals is critical for future growth [7] Group 6: Talent Acquisition and Team Structure - Dingcheng Peptide's R&D team includes 18 PhDs and 59 master's degree holders, ensuring expertise across key areas of drug development [10] - A recruitment plan aims to onboard 300 master's and doctoral graduates by 2025 to strengthen the R&D capabilities in cell therapy [10]

Group 1 - The company expects to achieve an operating revenue of approximately 135 million to 155 million yuan for the year 2025, representing an increase of 4.73 million to 24.73 million yuan compared to the previous year, with a year-on-year growth of 3.63% to 18.98% [1] - The projected net profit attributable to the parent company for 2025 is expected to be between -265 million to -225 million yuan, which is a reduction in losses by 175.72 million to 215.72 million yuan compared to the previous year, indicating a year-on-year decrease in losses of 39.87% to 48.95% [1] - The expected net profit attributable to the parent company, excluding non-recurring gains and losses, is projected to be between -274 million to -234 million yuan, reflecting a reduction in losses by 185.17 million to 225.17 million yuan compared to the previous year, with a year-on-year decrease in losses of 40.33% to 49.04% [2] Group 2 - The previous year's operating revenue was 130.27 million yuan [4] - The total profit for the previous year was -434.51 million yuan, with a net profit attributable to shareholders of -440.72 million yuan, and a net profit of -459.17 million yuan after excluding non-recurring gains and losses [5] - The earnings per share for the previous year was -0.67 yuan [6] Group 3 - The increase in operating revenue is attributed to the company's efforts in controlling sales, research and development, and management expenses, optimizing organizational structure, and improving resource utilization efficiency, leading to a decrease in overall costs and expenses compared to the previous year [7]

Meeting Summary - The 21st temporary meeting of the 9th Board of Directors of Jiangsu Lianhuan Pharmaceutical Co., Ltd. was held on January 23, 2026, via communication, with all 9 directors present, meeting the requirements of the company's articles of association [2][5]. Board Resolutions - The Board approved the proposal to establish a "Business Isolation System" to enhance risk management and ensure business separation between the company and its affiliated fund management entities, promoting stable and healthy development [3]. Financial Performance Forecast - The company forecasts a net profit attributable to shareholders for 2025 to be in the range of -99 million to -83 million RMB, indicating a decrease of 166.66 million to 183.16 million RMB compared to the previous year [7][9]. - The net profit after deducting non-recurring gains and losses is expected to be between -39 million and -32.5 million RMB, a reduction of 82.37 million to 88.87 million RMB year-on-year [7][9]. Previous Year Performance - In 2024, the net profit attributable to shareholders was 84.16 million RMB, and the net profit after deducting non-recurring gains and losses was 49.87 million RMB, with earnings per share at 0.29 RMB [10][11]. Reasons for Expected Loss - The expected loss is attributed to several factors, including pressure on gross margins from national drug procurement policies, adjustments in medical insurance payment policies, increased international market competition, administrative penalties leading to non-recurring expenses, and rising R&D costs due to increased investment in innovative drug development [11].

Group 1 - The company expects a loss of 54 million to 73 million yuan in 2025, with a non-recurring loss of 62 million to 84 million yuan [1] - The market environment has negatively impacted the company's sales revenue and gross margin due to fluctuations in terminal demand and declining market prices for certain raw material products [1] - The company's operational development is affected by high fixed costs during the gradual release of new production capacity from completed fundraising projects, as well as high unit costs from small-scale production of new health products set to launch in 2025 [1]

Core Viewpoint - Jinkai Biotechnology (301509.SZ) expects a significant increase in net profit for 2025, driven by improved terminal demand and order delivery pace [1] Financial Performance - The company anticipates a net profit attributable to shareholders ranging from 92 million to 116 million yuan, representing a year-on-year growth of 138.28% to 200.45% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 72 million and 91 million yuan, indicating a year-on-year increase of 314.69% to 424.12% [1] Operational Factors - The increase in delivered orders during the reporting period is attributed to the recovery in terminal demand and the rhythm of customer order deliveries [1] - The overall gross profit margin has improved due to the impact of the product structure of delivered orders [1]

（文章来源：证券日报） 证券日报网讯 1月23日，富祥药业发布公告称，公司董事会于近日收到公司副总经理陈应惠先生提交的 书面辞职报告，陈应惠先生因个人原因申请辞去公司副总经理职务，辞职后不再担任公司任何职务。 ...

Core Viewpoint - The company, Tuoxin Pharmaceutical, anticipates a significant increase in net profit loss for the fiscal year 2025, projecting a loss between 54 million to 73 million yuan, compared to a loss of approximately 19.88 million yuan in the previous year, indicating a decline of 171.56% to 267.11% year-over-year [1] Financial Performance - The projected net profit loss for 2025 is estimated to be between 54 million to 73 million yuan [1] - The previous year's loss was reported at 19.88 million yuan [1] - The anticipated decline in net profit loss represents an increase in losses by 171.56% to 267.11% compared to the previous year [1]